Skip to main content
. Author manuscript; available in PMC: 2015 Mar 29.
Published in final edited form as: Cancer Res. 2014 Nov 14;75(1):22–30. doi: 10.1158/0008-5472.CAN-14-2533

Figure 5.

Figure 5

Generation of Th1 immune responses in patients with ovarian cancer undergoing treatment with MV. A–C, mean pretreatment and posttreatment IFNγ ELIspot responses for four treated patients against tumor antigens and tetanus toxoid (TT). Each symbol is calculated from 12 replicates. D, mean pre- and posttreatment antibody responses to various purified tumor antigens as well as tetanus toxoid. Each bar represents the mean (SEM) levels antibodies calculated from duplicate samples from 31 patients with ovarian cancer treated with MV.